Molecular Partners AG

Clinical trials sponsored by Molecular Partners AG, explained in plain language.

Molecular Partners AG MOLN NASDAQ

A clinical-stage biotech company developing DARPin therapeutics.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 1

New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer

Disease control Recruiting now

This study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …

Phase 1/2 • Sponsor: Molecular Partners AG • Aim: Disease control

Last updated Jun 27, 2026 12:37 UTC

Molecular Partners AG

New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer